ImmunoGenesis plans to include patients with tumours such as colorectal, ovarian and triple-negative breast cancer in the trial. Credit: aslysun / Shutterstock.com.

ImmunoGenesis has dosed the first participant in its Phase Ia/Ib clinical trial of IMGS-001 for the treatment of relapsed or refractory advanced solid tumours.

The first patient was dosed at the University of Texas MD Anderson Cancer Center in Houston, US. 

The first-in-human, multicentre, open-label dose escalation and expansion trial will evaluate the pharmacokinetics, safety and initial anti-tumour activity of IMGS-001.

It includes adult subjects with locally advanced or metastatic solid tumours that are refractory to standard-of-care therapy. 

In the dose escalation part of the trial, ImmunoGenesis plans to include patients with tumours such as colorectal, ovarian and triple-negative breast cancer.

See Also:

A lead asset of the company, IMGS-001 is a dual-specific programmed cell death 1 ligand 1 (PD-L1)/programmed cell death 1 ligand 2 (PD-L2) monoclonal antibody.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The antibody has cytotoxic effector activity and is intended for treating immune-excluded cancers that are resistant to current immunotherapies.

In preclinical research, IMGS-001 was shown to offer improved response rates in head-to-head studies versus existing immunotherapies. 

In June 2023, the company received an investment of $4.5m from the Cancer Focus Fund for its Phase Ia/Ib trial of IMGS-001. 

ImmunoGenesis president and CEO James Barlow said: “Many tumours are not responsive to the current immunotherapies, representing a significant unmet need. 

“We believe that this study will deliver initial proof of concept for our groundbreaking multitasking approach of using a single molecule to address immunosuppression and PD-1 pathway blockade.”